© Drug Hunter Inc. 2018-2023
Home > CC-90011
selective, reversible LSD1 inhibitor
<100 mg orally QW, in Ph. II for 1L ES-SCLC
from 300k+ cmpd HTS, SBDD + opt.
J. Med. Chem., Oct. 9, 2020
Celgene/Bristol Myers Squibb, San Diego, CA
CC-90011 (Celgene/Bristol Myers Squibb (BMS)) selective, reversible LSD1 inhibitor clinical candidate)
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year